Clinical-stage biotechnology company developing disease-modifying medicines for rare and other proteinuric chronic kidney diseases
Clinical-stage biotechnology company developing disease-modifying medicines for rare and other proteinuric chronic kidney diseases. Its pipeline includes WAL0921, a humanized monoclonal antibody targeting soluble and membrane-bound uPAR, and WAL0623, a small molecule designed to stabilize and restore dynamin function in kidney cells.